Innovotech Inc. (TSX Venture Exchange:IOT; OTCQB:IOTCF) announced today that its subsidiary, Innovotech Labs Corporation, is receiving advisory services and research and development funding of up to $234,000 CAD from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The funding will support the development of new antimicrobial testing services for medical devices such as catheters, implants, and wound dressings.
The new testing methods address changes in international regulatory standards and meet the needs of medical device manufacturers in areas including proliferation, biofilm formation, and translocation of microorganisms. This work builds on foundational development initiated last year and advances it into more robust, fit-for-purpose testing. As customer programs expand, manufacturers are requesting more advanced testing that better reflects real-world use and provides clearer decision-making data. Strengthening these capabilities will expand the Company's service offerings, support regulatory readiness, and help customers demonstrate device safety and performance more effectively.
“This NRC IRAP support will help us to deepen our technical bench, problem solve for our customers and deliver solutions that reduce infections and complications for better health outcomes,” said Craig Milne, CEO of Innovotech. “It also positions us to meet rising client demand with higher-complexity testing and stronger technical support as standards and expectations continue to evolve.”
The announcement is significant for the medical device industry, which increasingly relies on antimicrobial coatings and materials to prevent infections associated with implanted devices. The ability to accurately test for biofilm formation and microbial translocation is critical for regulatory submissions to bodies such as the U.S. Food and Drug Administration and Health Canada. By enhancing its testing capabilities, Innovotech is positioning itself to help manufacturers meet these evolving requirements more effectively, potentially reducing the time and cost of bringing new medical devices to market.
Innovotech Inc. is a leading life sciences services and technology company specializing in contract research, analytical, and microbial testing within regulated healthcare markets. The Company is a recognized leader in biofilm science and antimicrobial testing and provides advanced laboratory services supporting medical device, pharmaceutical, and industrial product development. Innovotech combines deep scientific expertise with proprietary methodologies and products, including its widely used MBEC Assay® platform for high‑throughput antimicrobial and antibiotic testing. Operating through ISO‑certified and GMP‑accredited laboratories, Innovotech supports clients across multiple sectors and geographies, delivering reliable, decision‑enabling data aligned with regulatory expectations.
The NRC IRAP funding is a testament to the importance of Innovotech's work in addressing infection control challenges. As antimicrobial resistance becomes a growing global concern, advanced testing methods are crucial for developing effective preventive strategies. This support will enable Innovotech to deepen its technical expertise and deliver solutions that reduce infections and complications, ultimately contributing to better health outcomes for patients worldwide.
